Round robin trial

Zytomed Systems regularly participates in round robin trials for immunohistochemistry, in situ hybridization and quantitative PCR, which are carried out by the Quality Assurance Initiative Pathology (QuIP), NordiQC and the European Society of Pathology (ESP). Please find current certificates here.


NordiQC Run 59 2020 „ASMA“

Actin alpha, Smooth Muscle (ASMA), Clone 1A4 (MSK030) – Assessment Results

Download

NordiQC Run 59 2020 „p16 INK4a“

p16 INK4a, Clone JC2 (MSK123) – Assessment Results

Download

NordiQC Run 59 2020 „CD45 (LCA)“

CD45 (LCA), Clone PD7/26 and 2B11 (MSK045) – Assessment Results

Download

NordiQC Run 59 2020 „CD10“

CD10, Clone 56C6 (MSK070) – Assessment Results

Download

NordiQC Run 59 2020 „S100“

S100, Clone 4C4.9 (MSK050) – Assessment Results

Download

NordiQC Run 59 2020 „UroII/III“

Uroplakin II, Clone BC21 (MSK102) – Assessment Results

Download

NordiQC Run C7 „PD-L1 (TECENTRIQ ®, IC)“

PD-L1, Clone CAL10 (RBK063) – Assessment Results

Download

NordiQC Run C7 „PD-L1 (Keytruda ®, TPS/CPS)“

PD-L1, Clone CAL10 (RBK063) – Assessment Results

Download

NordiQC Run B29 2020 „PR“

PR, Clone SP42 (RBK020) – Assessment Results

Download

NordiQC Run B28 2019 „HER2 IHC“

HER2, Clone EP3 (RBK067) – Assessment Results

Download

NordiQC Run 58 2020 „TTF1“

TTF1, Clone SPT24 (MSK111) – Assessment Results

Download

NordiQC Run 58 2020 „NKX3.1“

NKX3.1, Polyklonal (RBK062) – Assessment Results

Download

NordiQC Run 58 2020 „MUM1“

MUM1, Clone SP114 (513-4140) – Assessment Results

Download

NordiQC Run 57 2019 „MSH2“

MSH2, Clone FE11 (MSG031) – Assessment Results

Download

NordiQC Run 55 2019 „CK5“

Cytokeratin 5 & 14, Clone XM26 + LL002 (MSK106) – Assessment Results.

Download

NordiQC Run 55 2019 „ER“

Estrogen Receptor, Clone SP1 (RBK018) – Assessment Results.

Download

NordiQC Run 56 2019 „Melan A (MLA)“

MART-1 (Melan-A), Clone M2-7C10 (MSK056) – Assessment Results.

Download

NordiQC Run C5 2019 „PD-L1 (uro)“

Focused on the accuracy of PD-L1 IHC assays in order to identify patients with urothelial carcinomas to be treated with Pembrolizumab as immune therapy, PD-L1, Clone CAL10 (RBK063) – Assessment Results.

Download

NordiQC Run C5 2019 „PD-L1 (lung)“

Focused on the accuracy of PD-L1 IHC assays in order to identify patients with non-small cell lung carcinoma (NSCLC) benefitting from immune therapy with Pembrolizumab, PD-L1, Clone CAL10 (RBK063) – Assessment Results.

 

Download


back to Certificates